Eurofins Scientific (BATS-CHIXE:ERFP) - Stock Price, News & Analysis

ERFP Stock Overview

Provides various analytical testing and laboratory services worldwide. More details

ERFP fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	3/6
Past Performance	1/6
Financial Health	4/6
Dividends	0/6

Rewards

Trading at 67.1% below our estimate of its fair value

Earnings are forecast to grow 18.32% per year

Risk Analysis

Has a high level of debt

Large one-off items impacting financial results

Eurofins Scientific SE Competitors

Ergomed

AIM:ERGO

UK£701.1m

hVIVO

AIM:HVO

UK£149.7m

Hikma Pharmaceuticals

LSE:HIK

UK£4.3b

Qiagen

NYSE:QGEN

US$9.5b

Price History & Performance

Summary of all time highs, changes and price drops for Eurofins Scientific
Historical stock prices
Current Share Price	€47.00
52 Week High	€61.57
52 Week Low	€42.87
Beta	0.74
11 Month Change	0.41%
3 Month Change	n/a
1 Year Change	-12.44%
33 Year Change	-59.07%
5 Year Change	0.99%
Change since IPO	413.55%

Recent updates

Shareholder Returns

	ERFP	GB Life Sciences	GB Market
7D	3.0%	0.9%	1.7%
1Y	-12.4%	-30.0%	8.3%

Return vs Industry: ERFP exceeded the UK Life Sciences industry which returned -30% over the past year.

Return vs Market: ERFP underperformed the UK Market which returned 8.3% over the past year.

Price Volatility

Is ERFP's price volatile compared to industry and market?
ERFP volatility
ERFP Average Weekly Movement	6.4%
Life Sciences Industry Average Movement	6.6%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	10.3%
10% least volatile stocks in GB Market	2.6%

Stable Share Price: ERFP has not had significant price volatility in the past 3 months compared to the UK market.

Volatility Over Time: Insufficient data to determine ERFP's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1987	61,798	Gilles Martin	www.eurofins.com

Eurofins Scientific SE, together with its subsidiaries, provides various analytical testing and laboratory services worldwide. The company offers a portfolio of various analytical methods and tests to evaluate the safety, identity, composition, authenticity, origin, traceability, and purity of various products. It provides services such as agroscience, including biological assessment, consumer and human, and environmental safety, product chemistry, regulatory consultancy, and seed services; agro testing; assurance, such as product inspection, auditing, certification, training and consultation of food, consumer products, healthcare and cosmetics, and food supplements; biopharma, and clinical diagnostics.

Eurofins Scientific SE Fundamentals Summary

How do Eurofins Scientific's earnings and revenue compare to its market cap?
ERFP fundamental statistics
Market cap	€8.89b
Earnings (TTM)	€325.90m
Revenue (TTM)	€6.72b

27.3x

P/E Ratio

1.3x

P/S Ratio

Is ERFP overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ERFP income statement (TTM)
Revenue	€6.72b
Cost of Revenue	€5.23b
Gross Profit	€1.49b
Other Expenses	€1.17b
Earnings	€325.90m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

Feb 26, 2025

Earnings per share (EPS)	1.72
Gross Margin	22.19%
Net Profit Margin	4.85%
Debt/Equity Ratio	55.3%

How did ERFP perform over the long term?

See historical performance and comparison

Dividends

1.1%

Current Dividend Yield

30%

Payout Ratio

ERFP Stock Overview

Rewards

Risk Analysis

Eurofins Scientific SE Competitors

AIM:ERGO

UK£701.1m

AIM:HVO

UK£149.7m

LSE:HIK

UK£4.3b

NYSE:QGEN

US$9.5b

Price History & Performance

Recent News & Updates

Eurofins Scientific SE to Report First Half, 2025 Results on Jul 24, 2025

Eurofins Scientific SE to Report Fiscal Year 2024 Results on Feb 26, 2025

Eurofins Scientific SE (ENXTPA:ERF) agreed to acquire clinical diagnostics operations in Spain from SYNLAB AG (HMSE:SYAB).

Eurofins Scientific SE (ENXTPA:ERF) acquired Infinity Laboratories, LLC from Imperial Capital Acquisition Fund VI and Imperial Capital Limited.

Eurofins Scientific SE Provides Earnings Guidance for the Fiscal Year 2024

Insufficient new directors

Recent updates

Eurofins Scientific SE to Report First Half, 2025 Results on Jul 24, 2025

Eurofins Scientific SE to Report Fiscal Year 2024 Results on Feb 26, 2025

Eurofins Scientific SE (ENXTPA:ERF) agreed to acquire clinical diagnostics operations in Spain from SYNLAB AG (HMSE:SYAB).

Eurofins Scientific SE (ENXTPA:ERF) acquired Infinity Laboratories, LLC from Imperial Capital Acquisition Fund VI and Imperial Capital Limited.

Eurofins Scientific SE Provides Earnings Guidance for the Fiscal Year 2024

Insufficient new directors

Insufficient new directors

Eurofins Scientific SE (ENXTPA:ERF) acquired Ascend Clinical, LLC.

Eurofins Scientific SE, Annual General Meeting, Apr 25, 2024

Eurofins Scientific SE, Annual General Meeting, Apr 25, 2024

New minor risk - Earnings quality

Full year 2023 earnings released: EPS: €1.61 (vs €3.02 in FY 2022)

First half 2023 earnings released: EPS: €0.79 (vs €1.52 in 1H 2022)

Eurofins Scientific SE Updates Revenue Guidance for Fiscal Year 2023 and year 2027

Upcoming dividend of €1.00 per share at 1.8% yield

Eurofins Scientific SE to Report First Half, 2023 Results on Jul 26, 2023

Full year 2022 earnings released: EPS: €3.16 (vs €3.91 in FY 2021)

Investor sentiment deteriorates as stock falls 15%

Eurofins Scientific SE to Report Fiscal Year 2022 Results on Feb 21, 2023

Eurofins Scientific SE to Report Q3, 2022 Results on Oct 18, 2022

Eurofins Scientific SE (ENXTPA:ERF) signed of an agreement to acquire unknown majority stake in QSAI Analysis and Research Center Co., Ltd.

Eurofins Scientific SE (ENXTPA:ERF) acquired Wessling Hungary Kornyezetvedelmi, Elelmiszerbiztonsagi, Egeszsegvedelmi Es Minosegugyi Sz.

First half 2022 earnings released: EPS: €1.62 (vs €2.09 in 1H 2021)

Eurofins Scientific SE Revised Earnings Guidance for the Fiscal 2022

Upcoming dividend of €1.00 per share

Eurofins Scientific SE (ENXTPA:ERF) agreed to acquire unknown majority stake in Ajal for Laboratories from Saudi Ajal Laboratories.

Eurofins Scientific SE (ENXTPA:ERF) acquires an unknown majority stake in Repertoire Genesis Inc.

Health Canada Approves Eurofins CDMO Alphora Inc.’s Standard Processing License for Synthetic Phytocannabinoids

Eurofins Scientific SE Provides Earnings Guidance for the Fiscal Year 2023 and 2024

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Eurofins Scientific SE to Report Q1, 2022 Results on Apr 21, 2022

Eurofins’ empowerDX Launches PFAS Exposure™ in the U.S, the First at-Home Blood Test to Detect and Measure 40+ PFAS Compounds

Eurofins Technologies Launches New Lateral Flow Reader Rapidscan ST5-W as Single Platform Validated for Multiple Food and Environmental Rapid Tests

Eurofins Scientific SE (ENXTPA:ERF) entered into a share purchase agreement to acquire GeneticLab Co., Ltd. from Trans Genic Inc. (TSE:2342).

Eurofins Technologies Launches New Multiplex RT-PCR Respiratory Panel for SARS-CoV-2, Flu A, Flu B, RSV A and RSV B

First half 2021 earnings released: EPS €2.17 (vs €0.43 in 1H 2020)

Eurofins Scientific SE (ENXTPA:ERF) acquired bioskin GmbH.

Upcoming dividend of €0.68 per share

Eurofins Launches a New Multiplex PCR Assay for Rapid Detection of the B.1.617 India Sars-Cov-2 Variant

Eurofins Scientific Adds Virus Variant Detection to its SARS-CoV-2 Monitoring Solution for Wastewater, Surface, Air and Worn Masks

Full year 2020 earnings released: EPS €2.71 (vs €0.82 in FY 2019)

Revenue beats expectations

Eurofins Environment Testing America Expands Reporting to 75 Compounds

Eurofins Scientific SE to Report Fiscal Year 2020 Results on Mar 01, 2021

Eurofins Scientific SE (ENXTPA:ERF) agreed to acquire Beacon Discovery, Inc.

Eurofins Adds Virus Variant Distinction to its Sars-Cov-2 Monitoring Solution for Wastewater, Food and Environmental Surfaces

Eurofins Launches New Ultra-Fast Extraction-Free RT-PCR Method and Upgrades its RT-PCR Assay for Use with Pharynx Gargle and Saliva Sample Matrices

New 90-day high: €78.37

New 90-day high: €73.50

Eurofins Genomics Launches Cost-Effective SARS-CoV-2 Full-Length Viral Genome Sequencing Services Essential in the Identification of Viral Mutations

Eurofins U.S. Clinical Diagnostic Laboratories At-Home COVID-19 Test Now Being Offered in All 50 States

Eurofins Technologies Launches New and Improved Lateral Flow Device Product Line for Allergen Detection in Foodstuffs and Environmental Samples

New 90-day low: €63.21

Eurofins Scientific SE (ENXTPA:ERF) acquired Taiyo Techno Research.

Eurofins Launches Sensitive, Fast and Cost-effective High Throughput SARS-CoV-2 Test Kits for Widely Available Sanger Sequencing Equipment

Eurofins U.S. Clinical Diagnostics Network Receives EUA Approval of At Home COVID-19 Test

Eurofins Scientific Se Launches Europe’S First Validated Test Method to Evaluate Filtration Capacity of Masks for Sars-Cov-2

Eurofins Scientific SE (ENXTPA:ERF) acquired SunDream Environmental Technical Co. Ltd., Blue Formosa Environmental Technical Co. Ltd., and Universe Environmental Technology Co. Ltd.

Shareholder Returns